Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a prime M&A target for giants jostling for their share of a potential $100 billion market. Read the full story on Forbes: https://www.forbes.com/sites/amyfeldman/2026/01/04/how-a-wall-street-analyst-started-a-4-billion-obesity-drug-company/ Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1 Fuel your success with